Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer

• Main Authors: Iver Nordentoft, Philippe Lamy, Karin Birkenkamp-Demtröder, Karey Shumansky, Søren Vang, Henrik Hornshøj, Malene Juul, Palle Villesen, Jakob Hedegaard, Andrew Roth, Kasper Thorsen, Søren Høyer, Michael Borre, Thomas Reinert, Niels Fristrup, Lars Dyrskjøt, Sohrab Shah, Jakob Skou Pedersen, Torben F. Ørntoft
• Format: Article
• Language: English
• Published: Elsevier 2014-06-01
• Series: Cell Reports
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211124714003404

Bladder cancer (or urothelial cell carcinoma [UCC]) is characterized by field disease (malignant alterations in surrounding mucosa) and frequent recurrences. Whole-genome, exome, and transcriptome sequencing of 38 tumors, including four metachronous tumor pairs and 20 superficial tumors, identified an APOBEC mutational signature in one-third. This was biased toward the sense strand, correlated with mean expression level, and clustered near breakpoints. A > G mutations were up to eight times more frequent on the sense strand (p < 0.002) in [ACG]AT contexts. The patient-specific APOBEC signature was negatively correlated to repair-gene expression and was not related to clinicopathological parameters. Mutations in gene families and single genes were related to tumor stage, and expression of chromatin modifiers correlated with survival. Evolutionary and subclonal analyses of early/late tumor pairs showed a unitary origin, and discrete tumor clones contained mutated cancer genes. The ancestral clones contained Pik3ca/Kdm6a mutations and may reflect the field-disease mutations shared among later tumors.